Halozyme Therapeutics, Inc. (HALO)
67.37
+0.01
(+0.01%)
USD |
NASDAQ |
Mar 06, 16:00
67.98
+0.61
(+0.91%)
After-Hours: 20:00
Halozyme Therapeutics SG&A Expense (TTM) : 207.09M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Johnson & Johnson | 23.68B |
| Skye Bioscience, Inc. | 16.93M |
| AIM ImmunoTech, Inc. | 10.06M |
| Stryker Corp. | 8.651B |
| Glaukos Corp. | 331.75M |